Limor Rubin

555 total citations
29 papers, 317 citations indexed

About

Limor Rubin is a scholar working on Infectious Diseases, Immunology and Rheumatology. According to data from OpenAlex, Limor Rubin has authored 29 papers receiving a total of 317 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Infectious Diseases, 7 papers in Immunology and 6 papers in Rheumatology. Recurrent topics in Limor Rubin's work include SARS-CoV-2 and COVID-19 Research (5 papers), COVID-19 Clinical Research Studies (5 papers) and Urticaria and Related Conditions (4 papers). Limor Rubin is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (5 papers), COVID-19 Clinical Research Studies (5 papers) and Urticaria and Related Conditions (4 papers). Limor Rubin collaborates with scholars based in Israel, United States and Macao. Limor Rubin's co-authors include Philip Lazarovici, Ariel Kenig, Fadi Kharouf, Linlin Liu, Yi-Zhou Jiang, Xingan Xing, Tangming Peng, Radgonde Amer, Oded Shamriz and Yuval Tal and has published in prestigious journals such as SHILAP Revista de lepidopterología, Frontiers in Immunology and Cytokine & Growth Factor Reviews.

In The Last Decade

Limor Rubin

25 papers receiving 311 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Limor Rubin Israel 10 128 58 52 48 31 29 317
José Guilherme Ferreira Marques Galvão Brazil 7 92 0.7× 46 0.8× 97 1.9× 73 1.5× 30 1.0× 26 403
Yitang Sun United States 11 58 0.5× 50 0.9× 76 1.5× 31 0.6× 15 0.5× 20 344
Elham Rajaei Iran 11 69 0.5× 39 0.7× 70 1.3× 57 1.2× 31 1.0× 37 366
Ariel Kenig Israel 8 86 0.7× 31 0.5× 99 1.9× 31 0.6× 34 1.1× 19 303
Bhawna Tomar India 6 132 1.0× 65 1.1× 117 2.3× 88 1.8× 23 0.7× 10 364
Thomas C. Chamberlain Canada 7 69 0.5× 40 0.7× 77 1.5× 51 1.1× 10 0.3× 8 292
Yiqun Hao China 8 96 0.8× 55 0.9× 94 1.8× 40 0.8× 28 0.9× 19 280
Milijana Janjusevic Italy 12 51 0.4× 24 0.4× 92 1.8× 45 0.9× 32 1.0× 29 438
Ujala Srivastava United States 10 59 0.5× 31 0.5× 125 2.4× 36 0.8× 32 1.0× 16 436

Countries citing papers authored by Limor Rubin

Since Specialization
Citations

This map shows the geographic impact of Limor Rubin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Limor Rubin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Limor Rubin more than expected).

Fields of papers citing papers by Limor Rubin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Limor Rubin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Limor Rubin. The network helps show where Limor Rubin may publish in the future.

Co-authorship network of co-authors of Limor Rubin

This figure shows the co-authorship network connecting the top 25 collaborators of Limor Rubin. A scholar is included among the top collaborators of Limor Rubin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Limor Rubin. Limor Rubin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Elbirt, Daniel, Keren Mahlab‐Guri, Ilan Asher, et al.. (2025). Clinical significance of very high IgE levels (≥1000 IU/mL): Population-based study of 118,211 adults. Journal of Allergy and Clinical Immunology Global. 4(2). 100403–100403. 1 indexed citations
2.
Elbirt, Daniel, Keren Mahlab‐Guri, Ilan Asher, et al.. (2025). IgE deficiency (<2.5 IU / mL ) in children: Clinical insights from a population‐based study of 123,393 subjects. Pediatric Allergy and Immunology. 36(4). e70092–e70092.
3.
Rubin, Limor, David Lavie, Hovav Nechushtan, et al.. (2024). Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events. Journal for ImmunoTherapy of Cancer. 12(10). e009658–e009658. 2 indexed citations
4.
5.
Elias, Shlomo, Limor Rubin, Oded Shamriz, et al.. (2023). Dupilumab for cancer-associated refractory pruritus. SHILAP Revista de lepidopterología. 2(3). 100128–100128. 10 indexed citations
6.
Rubin, Limor, et al.. (2023). Administration of BNT162b2 mRNA COVID-19 vaccine to subjects with various allergic backgrounds. Frontiers in Immunology. 14. 1172896–1172896. 1 indexed citations
7.
Tal, Yuval, Limor Rubin, Oded Shamriz, et al.. (2023). Fast Acting, Dry Powder, Needle-Free, Intranasal Epinephrine Spray: A Promising Future Treatment for Anaphylaxis. The Journal of Allergy and Clinical Immunology In Practice. 11(10). 3047–3054. 13 indexed citations
8.
Rubin, Limor, et al.. (2023). Novel targeted inhibition of the IL-5 axis for drug reaction with eosinophilia and systemic symptoms syndrome. Frontiers in Immunology. 14. 1134178–1134178. 13 indexed citations
9.
Rubin, Limor, et al.. (2023). Successful ligelizumab treatment of severe refractory solar urticaria. The Journal of Allergy and Clinical Immunology In Practice. 11(8). 2576–2577. 3 indexed citations
10.
Elbirt, Daniel, Keren Mahlab‐Guri, Ilan Asher, et al.. (2023). Food‐induced anaphylaxis during infancy is associated with later sleeping and eating disorders. Pediatric Allergy and Immunology. 34(12). e14061–e14061. 2 indexed citations
11.
Kharouf, Fadi, et al.. (2023). Increased rates of idiopathic inflammatory myopathies during the COVID-19 pandemic: a single-centre experience. Clinical and Experimental Rheumatology. 41(2). 316–321. 11 indexed citations
12.
Li, Qin, Limor Rubin, Marta Silva, et al.. (2022). Current Progress on Neuroprotection Induced by Artemisia, Ginseng, Astragalus, and Ginkgo Traditional Chinese Medicines for the Therapy of Alzheimer’s Disease. Oxidative Medicine and Cellular Longevity. 2022(1). 3777021–3777021. 17 indexed citations
13.
Shamriz, Oded, Limor Rubin, Anthony Simon, et al.. (2022). Dominant-negative signal transducer and activator of transcription (STAT)3 variants in adult patients: A single center experience. Frontiers in Immunology. 13. 1044933–1044933. 4 indexed citations
14.
Halasi, Marianna, Abraham Nyska, Limor Rubin, et al.. (2022). Melanocyte-secreted fibromodulin constrains skin inflammation in mice injected with lupus serum. Clinical Immunology. 241. 109055–109055. 4 indexed citations
15.
Jiang, Yi‐Zhou, Limor Rubin, Zhiwei Zhou, et al.. (2022). Pharmacological therapies and drug development targeting SARS-CoV-2 infection. Cytokine & Growth Factor Reviews. 68. 13–24. 8 indexed citations
16.
Asleh, Rabea, Elad Asher, Gabby Elbaz‐Greener, et al.. (2021). Predictors of Hypoxemia and Related Adverse Outcomes in Patients Hospitalized with COVID-19: A Double-Center Retrospective Study. Journal of Clinical Medicine. 10(16). 3581–3581. 5 indexed citations
17.
Gilon, Chaim, Haim Ovadia, Limor Rubin, et al.. (2021). Synthesis and Pharmacological Characterization of Visabron, a Backbone Cyclic Peptide Dual Antagonist of α4β1 (VLA-4)/α9β1 Integrin for Therapy of Multiple Sclerosis. SHILAP Revista de lepidopterología. 1(12). 2361–2376. 4 indexed citations
18.
Jiang, Yi-Zhou, Limor Rubin, Tangming Peng, et al.. (2021). Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy. International Journal of Biological Sciences. 18(2). 459–472. 79 indexed citations
19.
Kenig, Ariel, et al.. (2021). Autoimmune phenomena following SARS-CoV-2 vaccination. International Immunopharmacology. 99. 107970–107970. 64 indexed citations
20.
Rubin, Limor, et al.. (2021). Neurotrophic factors and their receptors in lung development and implications in lung diseases. Cytokine & Growth Factor Reviews. 59. 84–94. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by José Guilherme Ferreira Marques Galvão Breakdown of academic impact, for papers by Yitang Sun Breakdown of academic impact, for papers by Elham Rajaei Breakdown of academic impact, for papers by Ariel Kenig Breakdown of academic impact, for papers by Bhawna Tomar Breakdown of academic impact, for papers by Thomas C. Chamberlain Breakdown of academic impact, for papers by Yiqun Hao Breakdown of academic impact, for papers by Milijana Janjusevic Breakdown of academic impact, for papers by Ujala Srivastava
Rankless by CCL
2026